Molecular (vascular) · PMID 28539025
Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis — VialBase Research
Named, compound-specific vascular mechanism study for Vesugen.
Last updated · 2016 · Kozlov KL et al. · Adv Gerontol
Key findings
- KED (Vesugen) showed vasoprotective activity in atherosclerosis and restenosis contexts
- Supports the compound's positioning as a vascular bioregulator
KED vasoprotective activity (PMID: 28539025)
Summary
The KED tripeptide (Vesugen) demonstrated vasoprotective molecular effects in atherosclerosis and restenosis models.
Relevance
Core mechanistic evidence for Vesugen‘s vascular claims.
See Also
- Parent compound: Vesugen
Where to buy Vesugen
Vesugen3 vetted vendors
BioLongevity LabsVisit BioLongevity Labs →
Save 15% with code VIALBASE
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.